Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China
Tenacia is expected to drive the development and commercialization of ganaxolone in China across our current focus areas of CDKL5 deficiency disorder, tuberous sclerosis complex and status epilepticus, and to potentially play a key role in the development of a next generation ganaxolone formulation.
- Tenacia is expected to drive the development and commercialization of ganaxolone in China across our current focus areas of CDKL5 deficiency disorder, tuberous sclerosis complex and status epilepticus, and to potentially play a key role in the development of a next generation ganaxolone formulation.
- Partnering with Marinus to develop and commercialize ganaxolone in China positions us well to quickly become a pioneer in the development of treatments that target significant unmet medical needs for epilepsy patients, said Dr. Xiaoxiang Chen, Chief Executive Officer of Tenacia Biotechnology.
- We look forward to collaborating closely with Marinus while exploring the full potential of ganaxolone.
- Based in China, Tenacia Biotechnology (Shanghai) Co., Ltd. is an emerging biotech company focused on the development of innovative treatments for central nervous system (CNS) disorders.